FDA Attempts to Ban IV Vitamin C, Magnesium and B Vitamins

Posted on February 3, 2012 by steves

»

FDA Seeking to Outlaw IV Vitamin C, Other Nutrients

FDA Seeking to Outlaw IV Vitamin C, Other Nutrients
Rep. Ron Paul, MD: As an agency, FDA engages in “abuse of power…”

“FDA: Leave Our Nutrients and Supplements Alone!”
Action item: http://tinyurl.com/saveIVNutrients 

Archive of Emergency Web Meeting of January 9, 2011 here:
https://naturalsolutionsfoundation.webex.com/naturalsolutionsfoundation/ldr.php?AT=pb&SP=MC&rID=2625702&rKey=9f5c8c59f61ba89a

March 9, 2011 – We Dissect a Response from the FDA! Click Here.

The FDA (the Food Destruction Agency) not content with its new power to control and industrialize our entire food supply, is, quite predictably, increasing its attacks on nutrients. Although the mis-named Food Safety [sic!] Modernization Act excludes nutrients, the FDA’s rampage against natural health is by no means limited to degrading our food supply.

DSHEA, the 1994 Dietary Supplements Health and Education Act, which protects dietary supplements does not protect nutrients unless they are delivered in oral form. That means that intravenous, transdermal, nasal, suppository or other forms of nutrition are vulnerable to FDA assault in a particularly worrisome way. This latest action by the FDA makes that point clearly.

On December 28, 2010 FDA ordered certain small manufacturers to stop making IV Vitamin C and several other injectable nutrients which are always used under a (holistic or Advanced health Care) physician’s supervision by classifying IV Vitamin C, Magnesium and certain B Vitamins as “New Drugs”.

The nutrients under attack, which form the basis of the popular “Myers Cocktail” and countless therapies for serious diseases, may be provided ONLY by compounding pharmacies under a specific prescription for a specific patient. This means that the cost of these nutrients will increase sharply.

It also means that the FDA, always hostile to compounding pharmacies and the independent use of nutrients, bio-identical hormones (now banned at the request of Wyeth/Pfizer, which manufactures dangerous synthetic hormones), the biologically active form of Vitamin B-6 (also banned at the request of a drug company) can pick off individual substances and attack compounding pharmacies at their leisure. This is a result of the power granted FDA in 2007 (section 301(11) of the Kennedy FDA Enabling Act) to ban interstate sale of any “food” ever studied for medical use, even if never so used.

Why, you ask, does FDA need authority to ban safe foods? Why does Congress think it has the power to grant such authority? Where in the Constitution does Congress have that power? And please, don’t say it’s in the “Commerce Clause” which grants the Federal Government the power to regulate Interstate Commerce. “Regulate” does not mean the power to forbid foods that people have always had the fundamental human right to grow, trade and use. It merely means to make commerce regular; to make fair and neutral “rules of the road” for Interstate Commerce. Under the 9th Amendment, the People have retained the right to grow and trade foods, including vitamins and minerals. As we Restore the Republic, that right must be respected again.

Manufacturing companies wishing to make and sell the now restricted injectible, inexpensive and life-saving nutrients will be forced to engage in full-scale drug approval testing for products that cannot be patented; this, the FDA knows, is economically impossible. The attack on Vitamin C comes on the heels of efforts by FDA to ban other nutrients, including forms of Vitamin B6 banned under the Kennedy Enabling Act.

If these restrictions stand, what nutrient will be next?

Please take the Action Item at this link, which tells the White House and FDA to leave our nutrients alone! http://tinyurl.com/saveIVNutrients

Blog entry originally published at: http://vitaminlawyerhealthfreedom.blogspot.com/2011/01/fda-seeking-to-outlaw-iv-vitamin-c.html

Posted in Estrogen Replacement, Intravenous Vitamin C, Intravenous Vitamin C, Lymes Disease, mercury toxicity, Mycoplasma, Petitions | Tagged , , , , | 2 Comments

Case Report: Vitamin C IV Eliminated Shingles Pain

Posted on January 25, 2012 by steves

 

Med
Sci Monit. 2010 May;16(5):CS58-61.

Intravenous administration of vitamin C in the
treatment of herpetic neuralgia: two case reports.

Schencking
M, Sandholzer
H, Frese
T.

Source

Clinic St. Georg, Bad Aibling, Germany. naturedoc@web.de

Abstract

BACKGROUND:

Acute herpetic neuralgia (AHN) due to a reactivated varicella zoster virus
infection is a common problem. Furthermore, about 18% of all patients with
confirmed herpes zoster (HZ) develop postherpetic neuralgia (PHN). The leading
factors of the prognosis and persistence of symptoms are patient age and the
size of the lesions. Animal studies came to a similar conclusions that in both
AHN and PHN, inflammatory cytokines such as IL-6 and IL-8 could serve as
predictive markers and that a positive influence of vitamin C administration,
by modifying cytokine metabolism, could be demonstrated.

CASE REPORT:

Two patients (females aged 67 and 53 years) from an average and unselected
patient group of a general practice with confirmed AHN were observed in the
course of their illness. They received the basic analgesic (according to the
WHO step scheme) and viral-static therapy. Furthermore, 15 g of vitamin C was
administered intravenously every second day over a period of two weeks. Sudden
and total remission of the neuropathic pain (measured on the basis of the
visual analogous-scale, VAS) could be observed. Remission of the cutaneous
lesions was noted within 10 days.

CONCLUSIONS:

The use of the vitamin C appears to be an interesting component of
alternative therapeutic strategies in the treatment of HZ. Especially for
therapy-resistant cases of PHN, vitamin C administration should be examined as
an additional option. To test and confirm the clinical findings, randomized
clinical studies concerning the use of vitamin C in the concomitant treatment
of zoster-associated neuralgia should be performed.

Posted in Herpes, Intravenous Vitamin C | Tagged , , , , | Leave a comment

SOPA Bill Opposed by Copyright Attorneys

Posted on January 20, 2012 by steves

The OPEN bill, sponsored by Rep. Darrel Issa, offers a rational, workable solution to internet Copyright infringement, without threatening freedom of speech, political protest or legitimate corporate competition.  Please email your comments, recommendations or suggestions, regarding the OPEN act to http://keepthewebopen.com/

The proposed SOPA legislation appears to be designed to oppose political dissent and corporate competition, instead of reducing Copyright infringement and cyberpiracy.  The SOPA bill could penalize innocent websites, which were unknowingly victimized by zombie attacks.  Congress needs to invite copyright attorneys and internet security experts to help draft anticyberpiracy laws which would actually help control cyberpiracy.  If the only choice becomes protecting profits of Hollywood millionaires and billionaires or protecting the internet, the largest libray in the world, I choose  protecting the internet.  The world’s largest copyright infringer appears to be Google, which has been sued for infringement by American Airlines, Geico, Rosetta Stone and other large well known companies.  The most helpful step government could take to stop Copyright infringement or cyberpiracy would be to help victims of spamming, hacking and copyright infringement track the origin of cybertheft  and copyright infringement thru the layers and layers of websites and IP addresses, which many spammers and copyright thieves hide behind.  – Steve S

Copyright Lawyers Oppose SOPA … And Say It Won’t Even Work

George Washington's picture
Submitted by George
Washington on 01/09/2012 21:23 -0500
SOPA WON’T WORK
Many experts have said that SOPA and PIPA are not only draconian, but that
they fail to address the root problem.
A former intellectual property law school professor points out:
[SOPA and PIPA] aim to curb online copyright piracy … but end up using a
sledgehammer, when a fine scalpel is instead needed.
***
As reported by Forbes, the Atlantic Monthly
and others, coders are already developing
work-arounds to SOPA and
PIPA. For example, a developer using the alias
“Tamer Rizk” launched DeSopa,
an add-on for the popular Firefox browser that
would allow users to
visit sites blocked by the proposed copyright protection
measures
proposed under SOPA. So not only these bills are not only
draconian, but they won’t work.
Jay McDaniel – a plaintiff’s attorney for content providers fighting
torrent–based copyright infringement – agrees:
There is a simple solution to the dilemma of digital
piracy, however, one
that will cost the government nothing, that will
protect free speech and that
will ultimately bring an end to a practice
that is undermining the viability
of our cultural industries. More
importantly, it will enable Congress to
avoid polluting legitimate free
speech issues with behavior that is neither
protected by the
Constitution nor lawful.
Simply let copyright holders exercise the right to efficiently
discover
the identity of infringers. Copyright law as it presently
exists with its
substantial civil remedies will take care of the rest of
the problem.
***
The answer is simple. Congress should overrule two decisions that
held
that copyright owners could not use the Digital Millenium Copyright
Act
(DMCA) to subpoena the identities of infringers directly from cable
internet
service providers. These two decisions, Recording Indus.
Ass’n of America v.
Verizon Internet Servs., Inc., 351 F.3d 1299 (D.C.
Cir. 2003) and In re
Charter Communications, Inc., 393 F.3d 771 (8th
Cir. 2005), have made it
extremely difficult for copyright owners to
find and prosecute civil claims
against the wide-spread piracy that
occurs on peer-to-peer networks.
Both cases involved attempts by copyright owners to use a provision
in the
DMCA that allows the owners to issue takedown notices to Internet
Service
Providers (ISPs) and to also obtain a subpoena to learn the
identity of the
infringer. The Verizon and Charter Communications
courts held that the
takedown notice-subpoena provisions did not apply
to claims seeking to
discover the identity of Internet account holders.
It was a strained reading of the statute to begin with, and it has
led to
a morass of litigation and discovery disputes in which there are
conflicting
jurisdictional and venue decisions on a nearly daily basis.
More
significantly these decisions closed the courthouse doors to any
copyright
holder that cannot demonstrate widespread copying sufficient
to justify
bringing a large “John Doe” action just to find out who the
culprits are.
Moreover, in a relatively small number of cases, hostile
district judges are
unwilling to let the cases go forward in any
reasonably economic manner.
***
Copyright holders know that their works are being pirated. They know
where
they are being pirated and how they are being pirated. But they
simply cannot
get to the pirates. If Congress were to overrule these
decisions, the problem
would disappear as the people who break the law
would find themselves facing
the serious consequences of a civil
infringement suit. The infringers would
pay for the remedy through
statutory fee shifting.
Private enforcement litigation would replace the need for
government
oversight of our Internet habits, and those who break the law
would fund
the system. Digital piracy, in its present form, would quickly
come to
a halt for the same reason that we don’t shoplift copies of DVDs
from
Walmart. It’s too easy to get caught and the penalties are too severe.
As Harvard law school professor Lawrence Tribe wrote to Congress:
[SOPA] creates confusion and underscores the need to go
back to the
drawing board and craft a new measure that works as a
scalpel rather than a
sledgehammer to address the governmental interests
that SOPA purports to
advance.
COPYRIGHT LAWYERS ARE AGAINST SOPA
Indeed, many of the nation’s top copyright lawyers also oppose SOPA and PIPA,
including:
  1. Marvin Ammori, Affiliate Scholar, Center for Internet &
    Society, Stanford Law School
  2. Brook K. Baker, Northeastern University School of Law
  3. Stewart
    Baker, former NSA General Counsel and Head of Cyber Policy for DHS
  4. Derek E. Bambauer, Brooklyn Law School
  5. Margreth Barrett, Hastings College of Law University of
    California-San Francisco
  6. Mark Bartholomew, University at Buffalo Law School
  7. Ann M. Bartow, Pace Law School
  8. Marsha Baum, University of New Mexico School of Law
  9. Yochai Benkler, Harvard Law School
  10. Oren Bracha, University of Texas School of Law
  11. Annemarie Bridy, University of Idaho College of Law
  12. Chris Bronk, Rice University
  13. Dan L. Burk, University of California-Irvine School of Law
  14. Irene Calboli, Marquette University School of Law
  15. Adam Candeub, Michigan State University College of Law
  16. Michael Carrier, Rutgers Law School – Camden
  17. Michael W. Carroll, Washington College of Law American
    University
  18. Brian W. Carver, School of Information University of
    California-Berkeley
  19. Anupam Chander, University of California-Davis School of Law
  20. Andrew Chin, University of North Carolina School of Law
  21. Ralph D. Clifford, University of Massachusetts School of Law
  22. Julie E. Cohen, Georgetown University Law Center
  23. G. Marcus Cole, Stanford Law School
  24. Kevin Collins, Washington University-St. Louis School of Law
  25. Danielle M. Conway, University of Hawai’i Richardson School of
    Law
  26. Dennis S. Corgill, St. Thomas University School of Law
  27. Christopher A. Cotropia, University of Richmond School of Law
  28. Thomas Cotter, University of Minnesota School of Law
  29. Julie Cromer Young, Thomas Jefferson School of Law
  30. Ben Depoorter, Hastings College of Law University of California –
    San Francisco
  31. Eric B. Easton, University of Baltimore School of Law
  32. Anthony Falzone Director, Fair Use Project Stanford Law School
  33. Nita Farahany, Vanderbilt Law School
  34. Thomas G. Field, Jr., University of New Hampshire School of
    Law
  35. Sean Flynn, Washington College of Law American University
  36. Brett M. Frischmann, Cardozo Law School Yeshiva University
  37. Jeanne C. Fromer, Fordham Law School
  38. William T. Gallagher, Golden Gate University School of Law
  39. Laura N. Gasaway, University of North Carolina School of Law
  40. Deborah Gerhardt, University of North Carolina School of Law
  41. Llew Gibbons, University of Toledo College of Law
  42. Eric Goldman, Santa Clara University School of Law
  43. Marc Greenberg, Golden Gate University School of Law
  44. James Grimmelman, New York Law School
  45. Leah Chan Grinvald, St. Louis University School of Law
  46. Richard Gruner, John Marshall Law School
  47. Robert A. Heverly, Albany Law School Union University
  48. Laura A. Heymann, Marshall-Wythe School of Law College of William
    & Mary
  49. Herbert Hovenkamp, University of Iowa College of Law
  50. Dan Hunter, New York Law School
  51. David R. Johnson, New York Law School
  52. Faye E. Jones, Florida State University College of Law
  53. Amy Kapczynski, University of California-Berkeley Law School
  54. Dennis S. Karjala, Arizona State University College of Law
  55. Anne Klinefelter, University of North Carolina College of Law
  56. Mary LaFrance, William Boyd Law School University of Nevada – Las
    Vegas
  57. Amy L. Landers, McGeorge Law School University of the Pacific
  58. Mark Lemley, Stanford Law School
  59. Lawrence Lessig, Harvard Law School
  60. David S. Levine, Elon University School of Law
  61. Yvette Joy Liebesman, St. Louis University School of Law
  62. Peter Linzer, University of Houston Law Center
  63. Lydia Pallas Loren, Lewis & Clark Law School
  64. Michael J. Madison, University of Pittsburgh School of Law
  65. Gregory P. Magarian, Washington University-St. Louis School of
    Law
  66. Phil Malone, Harvard Law School
  67. Christian E. Mammen, Hastings College of Law University of
    California-San Francisco
  68. Jonathan Masur, University of Chicago Law School
  69. Andrea Matwyshyn, Wharton School of Business University of
    Pennsylvania
  70. J. Thomas McCarthy, University of San Francisco School of Law
  71. Aleecia M. McDonald, Stanford University
  72. William McGeveran, University of Minnesota Law School
  73. Stephen McJohn, Suffolk University Law School
  74. Mark P. McKenna, Notre Dame Law School
  75. Hiram Melendez-Juarbe, University of Puerto Rico School of Law
  76. Viva Moffat, University of Denver College of Law
  77. Ira Nathenson, St. Thomas University School of Law
  78. Tyler T. Ochoa, Santa Clara University School of Law
  79. David S. Olson, Boston College Law School
  80. Barak Y. Orbach, University of Arizona College of Law
  81. Kristen Osenga, University of Richmond School of Law
  82. Frank Pasquale, Seton Hall Law School
  83. Aaron Perzanowski, Wayne State University Law School
  84. Malla Pollack Co-author, Callman on Trademarks, Unfair
    Competition, and Monopolies
  85. David G. Post, Temple University School of Law
  86. Connie Davis Powell, Baylor University School of Law
  87. Margaret Jane Radin, University of Michigan Law School
  88. Glenn Reynolds, University of Tennessee Law School
  89. David A. Rice, Roger Williams University School of Law
  90. Neil Richards, Washington University-St. Louis School of Law
  91. Michael Risch, Villanova Law School
  92. Betsy Rosenblatt, Whittier Law School
  93. Matthew Sag, Loyola University-Chicago School of Law
  94. Pamela Samuelson, University of California-Berkeley Law School
  95. Sharon K. Sandeen, Hamline University School of Law
  96. Jason M. Schultz, UC Berkeley Law School
  97. Jeremy Sheff, St. John’s University School of Law
  98. Jessica Silbey, Suffolk University Law School
  99. Brenda M. Simon, Thomas Jefferson School of Law
  100. David E. Sorkin, John Marshall Law School
  101. Christopher Jon Sprigman, University of Virginia School of Law
  102. Katherine J. Strandburg, NYU Law School
  103. Madhavi Sunder, University of California-Davis School of Law
  104. Rebecca Tushnet, Georgetown University Law Center
  105. Deborah Tussey, Oklahoma City University School of Law
  106. Barbara van Schewick, Stanford Law School
  107. Eugene Volokh, UCLA School of Law
  108. Sarah K. Wiant, William & Mary Law School
  109. Darryl C. Wilson, Stetson University College of Law
  110. Jane K. Winn, University of Washington School of Law
  111. Peter K. Yu, Drake University Law School
  112. Tim Zick, William & Mary Law
Posted in SOPA, Uncategorized | Tagged , , , , , , , | Leave a comment

Complement C4a Elevated in Chronic Lyme Disease and AIDS

Posted on January 20, 2012 by steves
Scand J Immunol. 2009 Jan;69(1):64-9.

Complement split products c3a and c4a in chronic lyme disease.

Source

International Lyme and Associated Diseases Society, Bethesda, MD, USA. rstricker@usmamed.com

Abstract

Complement split products C3a and C4a are reportedly elevated in patients with acute Lyme disease. We have now examined these immunologic markers in patients with chronic Lyme disease compared to appropriate disease controls. The study population consisted of 29 healthy controls, 445 patients with chronic Lyme disease, 11 patients with systemic lupus erythematosus (SLE) and six patients with AIDS. The Lyme disease patients were divided according to predominant musculoskeletal symptoms (324 patients) or predominant neurologic symptoms (121 patients). C3a and C4a levels were measured by radioimmunoassay. All patients with chronic Lyme disease and AIDS had normal C3a levels compared to controls, whereas patients with SLE had significantly increased levels of this marker. Patients with predominant musculoskeletal symptoms of Lyme disease and AIDS patients had significantly increased levels of C4a compared to either controls, patients with predominant neurologic symptoms of Lyme disease or SLE patients. Response to antibiotic therapy in chronic Lyme disease was associated with a significant decrease in the C4a level, whereas lack of response was associated with a significant increase in this marker. In contrast, AIDS patients had persistently increased C4a levels despite antiretroviral therapy. Lyme patients with positive single-photon emission computed tomographic (SPECT) scans had significantly lower C4a levels compared to Lyme patients with normal SPECT scan results. Patients with predominant musculoskeletal symptoms of Lyme disease have normal C3a and increased C4a levels. This pattern differs from the increase in both markers seen in acute Lyme disease, and C4a changes correlate with the response to therapy in chronic Lyme disease. C4a appears to be a valuable immunologic marker in patients with persistent symptoms of Lyme disease

Posted in AIDS, Lupus, Lymes Disease | Tagged , , , , , , , , | Leave a comment

Thyme Oil Completely Inhibited Aspergillus, Penicillium and Trichoderma Mold Growth on Pine Wood

Posted on January 9, 2012 by steves

 

Thyme oil completely inhibited Aspergillus, Penicillium and
Trichoderma on Southern Pine

http://www.fpl.fs.fed.us/documnts/pdf2006/fpl_2006_yang001.pdf
AMERICAN WOOD PROTECTION ASSOCIATION

Multi-component Biocide Protects Wood from Fungi and Insects in UC2 Applications
Carol A. Clausen Vina W. Yang

US Department of Agriculture, Forest Service Forest Products Laboratory Madison, Wisconsin

ABSTRACT

Results that demonstrate wood protection from mold, decay
and termites in laboratory and above ground field tests are presented for an experimental synergistic biocide, called Durazol.

 

Keywords: biocide, moldicide, termiticide, decav/iingi,
termite, synergy

INTRODUCTION
Development of synergistic biocides to protect wood in
interior applications has been of particular interest since the recent increase of indoor mold infestations. Many products have been developed to address the recent influx of indoor mold infestations.
Researchers must emphasize the use of environmentally benign chemicals due to the need for safety of human occupants. Some typical strategies employed include one or more of the following: naturally occurring antimicrobial or insecticidal chemicals, synergistic combinations of chemicals, chemicals with known performance (and previous EPA registration). Unfortunately, safely controlling fungal growth in the same environment as human occupants is difficult to accomplish. Since fungi and humans are both eukaryotic, (i.e. higher multi-cellular organisms with organized nuclei), metabolic inhibitors of fungi are likely to be toxic to humans (Clausen and Yang 2005a). Use of naturally occurring antimicrobials needs to be approached with caution, since many but not all naturally occurring compounds are toxic in tissue culture. Chemicals with previous EPA approval are limited, but certainly, new, unique combinations of such chemicals can create new formulations withantimicrobial or insecticidal properties (Clausen and Yang
2003). Occasionally, combinations of known fungal or insect inhibitors are synergistic, i.e. combined chemicals are more effective than the individual components at higher concentrations. One such synergistic combination,
called Durazol, incorporates some known antimicrobials and insecticides, namely boric acid and propionic acid with a quaternary amine compound and an azole to provide protection against mold fungi, stain fungi, decay fungi, and termites at lower concentrations than any of the individual components alone (Clausen and Yang 2004; 2005b; 2005c; 2007). A patent application was filed with the US Patent and Trade Office (USPTO) on 3/21/07 (Clausen et al. 2007).
MATERIALS AND METHODS
Organisms

Mold fungi: Three mold fungi, Aspergi/lus niger 2.242,
Penicilliu,n chrysogenum PH02 and Trichoderma viride ATCC 20476 were grown and maintained on 2% malt agar (Difco, Detroit, MI, USA) at 27°C, and 80% relative humidity (RH). Aureobasidium
pullulans MDX- 18 was grown and maintained on 2% potato dextrose agar at 27°C, and 80% relative humidity.
Spore suspensions of test fungi were prepared by washing the surface of individual 2-wk old Petri plate cultures with 10-15 ml of sterile deionized water (Dl) according to ASTM standard D4445-91 (ASTM 1998). The wash water was transferred to a spray bottle and diluted to approximately 100 mL with DI water to yield -3 x spores/ml. The spray bottle was adjusted to deliver 1 niL inoculum per spray. Individual spore suspensions were used to inoculate

31AMERICAN WOOD PROTECTION ASSOCIATION

monoculture Petri plate tests or the mold test chamber,
while  Aureobasidium pullulans was used exclusively for inoculation of the mold chamber test.

Decay fungi: Two brown-rot fungi, Gloeophyllum traheuin
Mad-563 and Postia placenta Mad-698 and one white-rot fungus, Trametess versicolor Mad-697 were grown and maintained on 2% malt extract agar at 27°C and 70% RH.
Termites: Subterranean termites, Reticulitermesfiavipes were
collected in Janesville, WI and maintained at the Forest Products Laboratory, Madison, WI.
Coptotermesformosanus were collected and maintained at the Fonnosan Termite Research Facility in McNeill, MS.

Chemical formulation

Durazol’s chemical formulation consists of  0.5% propionic acid, 0.1% boric acid, 1.1% dimethyl cocoamine, 0.1% thiabendazole and 0.3% propylene glycol in
an aqueous solution, however, due to low solubility, thiabendazole must be solubilized in 70% ethanol prior to addition to the treatment solution.

Treatment method and chemical retention

Unseasoned southern pine specimens were brushed, sprayed, or
immersed (15 sec) in treatment solution.

Chemical treatment retentions were determined from the
average difference in specimen weight before and after dipping and reported based on the volume of the specimen. Specimeds were held in a closed container for 24 hr at 25°C prior to challenge with test organisms.
Additionally, chemical retention in unseasoned pine was compared with kiln-dried pine. Retention rates were also compared for unseasoned pine, aspen, and Douglas-fir.

Mold test

Petri plate test: Five treated specimens and untreated
controls were placed in a Petri dish (150x25mm)

(B-D Falcon, Los Angeles, Calif.) containing four layers of
blotting paper that was saturated with 30 ml.DI water. A polyethylene mesh spacer was used to elevate specimens and prevent chemical leaching.

Specimens were sprayed with I mL of individual spore
suspension 24 hr post-treatment. Petri dishes weresealed in polyethylene bags to prevent drying, and incubated
at 27°C, 70% RH. Specimens wereindividually rated for mold growth at 4 and 8 wk on a scale
of 0 to 5 with 0 indicating no growth and
5 indicating heavy growth.

Environmental chamber test: A polypropylene mold chamber
fabricated according to ASTM 3273-00 (ASTM 1986) was placed in a room maintained at 30°C and 70% RH. The mold chamber relies on a circulating fan above water to provide 100% humidity and non-sterile soil for a supplemental source of circulating mold spores. The soil was additionally inoculated with mold spores from three test fungi,Aureobasidium pullulans, Aspergillus niger and Penicilliu,n
chrvsogenum, two weeks before placing the test specimens in the chamber. Five southern pine test specimens (75 x 100 mm by 12.5 mm thick) were conditioned at 27°C, 70% RH and weighed prior to immersion in Durazol for —15 sec. Treated specimens were reweighed and held for 24 hr in a closed container.
Treated specimens and untreated controls were vertically suspended across the width of the environmental chamber over inoculated soil. Specimens were sprayed with spore suspensions of A. niger, P. chrysogenum and T viride and incubated at 30°C. After 8 wk incubation, specimens were individually rated for mold growth on a scale of 0 to 5 with 0 indicating no growth and 5 indicating 100% coverage.

Soil block decay test

 

Soil block culture bottles were prepared according to AWPA
El 0 (2006) with a modification of wood block size to 1 x 1 x 1 cm. In soil block bottles, southern yellow pine feeders were inoculated with brownrot fungi, G. trabeum and P. placenta and maple feeders were inoculated with the white-rot fungus, T. versicolor. Bottles were incubated at 27°C and 70% RH for 3 weeks until the fungus completely colonized each feeder. Pre-weighed southern yellow pine or maple blocks, conditioned at 27°C and 70% RH, were vacuum treated with 2 % Durazol for 2 x 20 min at 25 in Hg.
Based on solution uptake, the boron retention in the blocks was 0.048 pcf (as B 2 03 ). The total Durazol retention was 0.97 pcf. Treated blocks were conditioned for 2 wk at 27°C, 70% RH and reweighed before adding them to pre-grown soil block bottles and incubating at 27°C, 70% RH for 12 weeks. Untreated blocks served as controls. Following incubation, surface mycelia was removed and blocks were dried at 60°C overnight before reconditioning at 27°C, 70% RH for 2 wk. Blocks were reweighed and the average percent weight loss was calculated.

Termite test

A laboratory no-choice test was conducted according to AWPA
El (2006) with  Reticu/itermesjlavipes at USDA Forest Products Laboratory in Madison, WI and on Coploterines formosanus at the Formosan Termite Research Facility at McNeill. MS.
Above ground test methods

Ground proximity test: A standard test for evaluation of
preservative treatments for lumber and timbers against subterranean termites in above-ground, protected applications (UCI and UC2) (AWPA E21) was initiated in July 2006 on southern yellow pine pressure-treated with 2% or 4% Durazol (0.97 and 1.93 pcf, respectively), disodium octaborate tetrahydrate (0.37 pet),
and untreated controls (N=I0). Specimens willbe evaluated annually for termite and fungal decay.

Above ground deck test: Five 2″ x 6″ x 30″
long southern pine deck boards were pressure treated with
2% Durazol and installed in a moderate decay hazard zone in
Madison. WI. After 2 years, there are nosigns of decay, mold, or stain on any surface of the treated specimens. They are rated as sound with no evidence of weakening, softening, or discoloration from deteriorating organisms.
32AMERICAN WOOD PROTECTION ASSOCIATION

RESULTS AND DISCUSSION

Chemical Retention

Comparative retention rates for Durazol applied by spray,
brush and dip are shown in Table 1. Brushing

and immersion provide roughly twice the treatment that
spraying does. Retention rates for different wood

types dip-treated with Durazol and the comparison of
kiln-dried with unseasoned SYP are shown in Table

2. Pine retains the most treatment whether it is kiln-dried
or unseasoned. Unseasoned Douglas-fir and aspen

demonstrate similar retention rates, although they both
retained approximately 3.4 times less than kiln-dried

pine and 1.5 times less than unseasoned pine.

Table I. Comparison of Durazol retention rate for brush,
spray and dip application on southern

yellow pine.

Ave.

Application

retention

method

(kg/rn)

Spray 0.54

Brush 0.95

Dip         0.83

33AMERICAN WOOD PROTECTION ASSOCIATION

Table 2. Comparative retention of different wood types and
seasoning conditions dip-treated with

Posted in Essential Oils, Mold Remediator Recommendation, Trichothecene | Tagged , , , , , , , , , , , | 4 Comments

Lactoferrin Decreases Inflammation Production By Lyme Spirochetes, Klebsiella and Other Gram Negative Bacteria

Posted on January 7, 2012 by steves

Lactoferrin Decreased LPS septic shock by
inhibiting L Selectin

FEBS Lett. 2000 Mar
3;469(1):5-8.
Lactoferrin is available over the counter in concentrated bovine colostrum supplements and the following study abstract reveals lactoferrin reduced inflammation production from gram negative bacteria endotoxins.  Klebsiella, Borrelia and Psuedomonas are some of the more common disease causing bacteria which produce the toxic Lipopolysaccharide, LPS, endotoxin.

Lactoferrin inhibits the binding of lipopolysaccharides to L-selectin and subsequent production of reactive oxygen species by neutrophils.

Baveye S, Elass E, Mazurier J, Legrand D.
Laboratoire de Chimie Biologique, Unité Mixte
de Recherche du CNRS no. 8576, Université des Sciences et Technologies de
Lille, 59655, Villeneuve d’Ascq, France.

Abstract

The activation of leukocytes by lipopolysaccharides (LPS),
resulting in the oxidative burst, contributes to the pathogenesis of septic
shock. The binding of LPS to L-selectin, which was reported as a
serum-independent LPS receptor on neutrophils, induces the production of oxygen
free radicals. Human lactoferrin (hLf), an anti-inflammatory glycoprotein
released from neutrophil granules during infection, binds to LPS. In this
study, we investigated the capacity of hLf to inhibit the L-selectin-mediated
activation of neutrophils. Our experiments revealed that hLf prevents the
binding of LPS to L-selectin in a concentration-dependent manner. Inhibition
was maximum (87.7+/-0.5%) at a concentration of 50 microg/ml of hLf.
Furthermore, hLf inhibited up to 55.4+/-0.5% of the intracellular hydrogen
peroxide production induced by LPS in neutrophils. These findings suggest that
the anti-inflammatory properties of hLf are due, at least in part, to their
ability to prevent the binding of LPS to neutrophil L-selectin.

 

Posted in Antioxidants, Lymes Disease, neurotoxin | Tagged , , , , , , , , , | Leave a comment

Boric Acid Reduced Aflatoxin B1 Toxicity

Posted on January 7, 2012 by steves

Cytotechnology.
2010 Apr;62(2):157-65. Epub 2010 Apr 30.

Boric acid: a potential chemoprotective agent against aflatoxin b(1) toxicity in human blood.

Turkez H,
Geyikoglu F.
Source

Department of Biology, Faculty of Sciences, Atatürk University,
25240, Erzurum, Turkey, hasanturkez@yahoo.com.

Abstract

Aflatoxin B(1) is the most potent pulmonary and hepatic
carcinogen. Since the eradication of Aflatoxin B(1) contamination in
agricultural products has been difficult, the use of natural or synthetic free
radical scavengers could be a potential chemopreventive strategy. Boric acid is
the major component of industry and its antioxidant role has recently been
reported. The present study assessed, for the first time, the effectiveness of
boric acid following exposure to Aflatoxin B(1) on human whole blood cultures.
The biochemical characterizations of glutathione and some enzymes have been
carried out in erythrocytes. Alterations in malondialdehyde level were
determined as an index of oxidative stress. The sister-chromatid exchange and
micronucleus tests were performed to assess DNA damages in lymphocytes. Aflatoxin B(1) treatment significantly reduced the activities of antioxidants by increasing malondialdehyde level (30.53 and 51.43%) of blood, whereas, the boric acid led to an increased resistance of DNA to oxidative damage induced by Aflatoxin B(1) in comparison with control values (P < 0.05). In conclusion, the support of boric acid was especially useful in Aflatoxin-toxicated blood. Thus the risk on tissue targeting of Aflatoxin B(1) could be reduced ensuring early recovery from its toxicity.

Posted in Aflatoxin | Tagged , , , , , , | 1 Comment

Alternative Complement Proteins Increased in Lupus

Posted on January 3, 2012 by steves

 
This peer reviewed journal indicates increased levels of inflammatory C3a and C5a anaphylatoxins were found in lupus patients.  Since Lyme Disease and indoor mold toxins also elevate C3a and other alternative complement anaphylatoxins, this study helps implicate Lyme disease and mold toxins as possible causes or aggravators of lupus symptoms.

Arthritis Rheum.
1986 Sep;29(9):1085-9.

Belmont HM, Hopkins P, Edelson HS, Kaplan HB, Ludewig R, Weissmann G, Abramson S.

 

Abstract
To determine whether activated complement components appear
in the circulation of patients with systemic lupus erythematosus (SLE), we
measured C5a and C3a by radioimmunoassay. Mean C5a concentration in the plasma of acutely ill SLE patients was 46.0 ng/ml, compared with 17.1 ng/ml in normal controls (P less than 0.01). Mean C3a concentration in patients with severe disease was 526 ng/ml, compared with 134 ng/ml in controls (P less than 0.01). In patients with moderately active SLE, the mean C3a concentration, but not the mean C5a concentration, was also elevated. In addition, C3a was elevated in 15 or 21 patients with active SLE, whereas low levels of C3 or C4 were noted in
only 7 of these 21 patients. We conclude that the measurement of complement-derived anaphylatoxins may be useful in the management of patients with SLE. In
addition, we suggest that these circulating mediators may contribute to the
pathogenesis of vascular injury in patients with the disease.

Posted in Lupus | Tagged , , , , , , , | 1 Comment

Why Do Physicians Continue Prescribing Xanax For Chronic Anxiety Instead of Valium or Tranxene?

Posted on January 2, 2012 by steves

Xanax seems to be far more addictive than longer half-life Valium or Tranxene, yet Physicians continue prescribing shorter half life Xanax, for patients who have anxiety 24 hours a day, seven days per week.  I believe Tranxene and Valium are also less expensive.

I have never been on any of these meds myself, but the people I have seen who have been prescribed Xanax all seem to have continual anxiety, not just panic attacks a few hours daily.

 

 

 

Posted in Addiction, Anxiety, Panic Disorder, Xanax | Tagged , , , | Leave a comment

Ozonation Appears Inadequate Against Stachybotrys chartarum Black Mold Spores

Posted on July 19, 2011 by steves

The chart on page four of the following article indicates most Stachybotrys chartarum spores survived exposure to high ozone concentrations for a 24 hour period. Stachybotrys chartarum can outgas extremely toxic trichothecene neurotoxins from behind wall cavities.

Real Time Lab offers urine mycotoxin testing for trichothecene, which is sensitive to 0.2 parts per billion.  Mold toxic patients frequently test positive for mold toxins in their urine, when air mold spore testing in their homes or offices did not find the source of the mold toxins.  Trained mold sniffing dogs are far more sensitive to mold neurotoxins, than air mold spore testing, although some of the trained dogs appear to be booked weeks in advance.

http://fss.k-state.edu/research/reports/OrtegaFrankenHatesohlMarsden200510.pdf

Posted in mold toxins, neurotoxin, Trichothecene | Tagged , , , , , | Leave a comment